

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

LN-18

RRID:CVCL_0392

Type: Cell Line

Proper Citation

RRID:CVCL_0392

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0392

Proper Citation: RRID:CVCL_0392

Description: Cell line LN-18 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: [PMID:7211194](#), [PMID:7693337](#), [PMID:7732013](#), [PMID:8509230](#), [PMID:9842975](#), [PMID:10416987](#), [PMID:14614447](#), [PMID:14655754](#), [PMID:17595512](#), [PMID:21406405](#), [PMID:22460905](#), [PMID:22570425](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25894527](#), [PMID:26496030](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: LN-18

Synonyms: LN 18, LN18, LN018

Cross References: BTO:BTO_0002005, CLO:CLO_0007362, EFO:EFO_0006636, MCCL:MCC:0000287, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2610, BCRJ:0420, BioGRID_ORCS_Cell_line:410, BioSample:SAMN03471122, BioSample:SAMN10988197, cancercellines:CVCL_0392, Cell_Model_Passport:SIDM00685, ChEMBL-Cells:ChEMBL4295405, ChEMBL-Targets:ChEMBL4296458, CLS:305822,

Cosmic:849858, Cosmic:1746957, Cosmic:1995484, Cosmic:2302322, Cosmic:2367489, Cosmic:2491101, Cosmic-CLP:1240168, DepMap:ACH-000819, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240168, GEO:GSM326196, GEO:GSM397661, GEO:GSM397662, GEO:GSM887269, GEO:GSM888344, GEO:GSM1374620, GEO:GSM1670048, IARC_TP53:2570, LiGeA:CCLE_635, LINCS_LDP:LCL-1353, Lonza:1681, PharmacDB:LN18_839_2019, PRIDE:PXD000589, PRIDE:PXD030304, Progenetix:CVCL_0392, PubChem_Cell_line:CVCL_0392, Wikidata:Q54902768

ID: CVCL_0392

Record Creation Time: 20220427T220730+0000

Record Last Update: 20260920T004357+0000

Ratings and Alerts

No rating or validation information has been found for LN-18.

No alerts have been found for LN-18.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Meena D, et al. (2026) Innate Immune Receptor NLRX1: Potential Modulator of Glioblastoma Pathophysiology. Journal of cellular physiology, 241(3), e70163.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

O'Loughlin TA, et al. (2026) mTORC1 activity suppresses ferroptosis through a SCARB1-dependent HDL-tocopherol uptake pathway. Molecular cell, 86(8), 1546.

Rurka P, et al. (2026) A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose-driven glioblastoma. Molecular oncology.

Bien-M??ller S, et al. (2025) The protease-activated receptors are expressed in glioblastoma and differentially modulate adherent versus stem-like growth of LN-18 GBM cells. Frontiers in oncology, 15, 1582996.

Yuan L, et al. (2025) Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degradar of the Nuclear Pore Complex. Cancer discovery, 15(12), 2505.

Lee YB, et al. (2024) Function of a complex of p-Y42 RhoA GTPase and pyruvate kinase M2 in EGF signaling pathway in glioma cells. *Journal of neurochemistry*.

Sallbach J, et al. (2024) The cell cycle inhibitor p21CIP1 is essential for irinotecan-induced senescence and plays a decisive role in re-sensitization of temozolomide-resistant glioblastoma cells to irinotecan. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 181, 117634.

Hesse J, et al. (2024) Intercellular crosstalk shapes purinergic metabolism and signaling in cancer cells. *Cell reports*, 43(1), 113643.

Tang M, et al. (2024) Inhibition of thioredoxin reductase 1 sensitizes glucose-starved glioblastoma cells to disulfidptosis. *Cell death and differentiation*.

Leszczynska KB, et al. (2024) H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells. *Cell reports*, 43(2), 113707.

Tan IL, et al. (2023) Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysis. *Cell reports*, 42(11), 113339.

Nguyen TT, et al. (2023) Epigenetic silencing of HTATIP2 in glioblastoma contributes to treatment resistance by enhancing nuclear translocation of the DNA repair protein MPG. *Molecular oncology*, 17(9), 1744.

Kim JY, et al. (2023) Jagged1 intracellular domain/SMAD3 complex transcriptionally regulates TWIST1 to drive glioma invasion. *Cell death & disease*, 14(12), 822.

Ham SW, et al. (2023) Annexin A2 Stabilizes Oncogenic JAG1 Intracellular Domain by Inhibiting Proteasomal Degradation in Glioblastoma Cells. *International journal of molecular sciences*, 24(19).

Patrick S, et al. (2023) Reduced YAP1 and FOLR1 in gliomas predict better response to chemotherapeutics. *Cellular signalling*, 109, 110738.

Zhang B, et al. (2022) Targeting BCAT1 Combined with α -Ketoglutarate Triggers Metabolic Synthetic Lethality in Glioblastoma. *Cancer research*, 82(13), 2388.

Han W, et al. (2022) Targeting HOTAIRM1 ameliorates glioblastoma by disrupting mitochondrial oxidative phosphorylation and serine metabolism. *iScience*, 25(8), 104823.

Shi Z, et al. (2022) Argininosuccinate lyase drives activation of mutant TERT promoter in glioblastomas. *Molecular cell*, 82(20), 3919.

McKinney AM, et al. (2022) GABP couples oncogene signaling to telomere regulation in TERT promoter mutant cancer. *Cell reports*, 40(12), 111344.